GHRP-2

Pralmorelin; KP-102; growth-hormone-releasing peptide 2

Identity

Sequence

(D-A)-(D-2-Nal)-A-W-(D-F)-K-NH2

Three-letter

D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂

Length

6 residues

Modifications

D-Ala¹; D-2-naphthylalanine²; D-Phe⁵; C-terminal amide

Formula

C45H55N9O6

Average mass

818.0 Da

CAS

158861-67-7

Specifications (per released lot)

Purity

≥ 98 % by RP-HPLC, 220 nm

Identity

ESI-MS; observed mass within 0.1 % of calculated

Form

White to off-white lyophilized powder

Counter-ion

Trifluoroacetate; acetate on request

Net peptide content

Reported per lot (typically 70–90 % of gross mass; the balance is counter-ion and water)

Vial sizes

5 mg · 10 mg · 25 mg net peptide; bulk on quotation

Storage

−20 °C, desiccated, protected from light. Ships at ambient temperature.

Documents

Lot certificate of analysis (COA library); safety data sheet in WHMIS 2015 format, enclosed with every shipment

Research context

Synthetic hexapeptide GHS-R1a agonist. Used in growth-hormone secretagogue receptor pharmacology and pituitary signalling studies. Authorized in Japan as a diagnostic agent; not authorized in Canada or the United States.

Literature context is provided to help laboratories identify the reagent. It is not a claim about effects in people and does not describe any use outside in-vitro or approved animal research.